TBP1901 / Therabiopharma - LARVOL DELTA

Development of an innovative anticancer drug TBP1901, an injectable prodrug of curcumin, for the treatment of multiple myeloma (AACR-NCI-EORTC 2025) - "In this study, we evaluated the mechanisms for the conversion of TBP1901 to curcumin in vivo as well as its antitumor effects on bortezomib (BTZ)-resistant multiple myeloma (MM) xenograft model. TBP1901 can exert antitumor effects on multiple myeloma as a prodrug of curcumin through GUSB-dependent activation. Genome-wide CRISPR-Cas9 screen revealed that essential therapeutic targets of curcumin constitute NF-ҡB signaling pathway and ROS production. Thus, TBP1901 could be a promising anticancer drug for the treatment of MM."

Hematological Malignancies • Multiple Myeloma • Oncology